Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation

Oral anticoagulation therapy is the mainstay of stroke prevention in nonvalvular atrial fibrillation patients. Vitamin K antagonists (such as warfarin) have been effective conventional oral anticoagulants for several decades. However, due to their limitations in clinical use, several nonvitamin K an...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2015-08, Vol.4 (4), p.367-376
Main Authors: Xiong, Qinmei, Lau, Yee C, Lip, Gregory YH
Format: Article
Language:English
Subjects:
Apixaban
Atrial fibrillation
Atrial Fibrillation - complications
Comparative analysis
Drug therapy
Edoxaban
Factor Xa Inhibitors - pharmacology
Humans
Prevention
Pyrazoles - pharmacology
Pyridines - pharmacology
Pyridones - pharmacology
Stroke
Stroke - complications
Stroke - prevention & control
Thiazoles - pharmacology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oral anticoagulation therapy is the mainstay of stroke prevention in nonvalvular atrial fibrillation patients. Vitamin K antagonists (such as warfarin) have been effective conventional oral anticoagulants for several decades. However, due to their limitations in clinical use, several nonvitamin K antagonist oral anticoagulants (NOACs, including dabigatran, rivaroxaban, apixaban and edoxaban) have been developed. Nonetheless, no head to head trials have been performed to directly compare these NOACs in patient cohorts. In this review article, two direct factor Xa inhibitors, apixaban and edoxaban, are briefly described with focus on their pharmacokinetic and pharmacodynamic profiles, plus drug interactions. Moreover, both efficacy and safety will be discussed based on the available data from the large Phase III clinical trials and indirect comparison studies.
ISSN:2042-6305
2042-6313
DOI:10.2217/cer.15.15